Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 3. Rapid correction of low vitamin D status in nursing home residents 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
See Latest ArticlesThe value of drugs for obesity in the management of cardiovascular risk factors
Sang Thrombose Vaisseaux, 11/04/09
Czernichow S et al. – Clinical trials show that the expected weight loss is 3 to 4 Kg compared with placebo. In addition, orlistat should improve blood sugar and lipid levels and reduce blood pressure. Sibutramine increases HDL cholesterol, decreases triglycerides but increases the blood pressure and heart rate. A trial is underway to study the impact of these adverse effects in subjects at high cardiovascular risk. Therefore, the field for the development of new drugs for treating overweight and obesity remains wide open.
Today in Atherosclerosis/Lipids...keeping you current
Receive free subspecialty "5-minute updates" via email
Nutritional supplements and serum lipids: Does anything work
Current Atherosclerosis Reports, 11/16/09
Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for Dyslipidemia
Annals of Internal Medicine, 11/03/09
Carbohydrate-restricted diets for obesity and related diseases: An update
Current Atherosclerosis Reports, 11/17/09
Sponsor
Article Search
Sponsor